The original article [1] contains errors in Figure 3i, Figure 6c and Figure S9:
1.
In Fig. 3i, the legends of the line chart were marked incorrectly.
Fig. 3
i Immunofluorescence analysis of co-localization between LA (green, FITC) and different subcellular compartments (red, early endosome, lysosome or endoplasmic reticulum) in immature DCs (blue, DAPI, nuclear) (n = 3)
×
2.
In Fig. 6c, the panel of ISA CD8a+ group was unintentionally duplicated onto the panel of YL-ISA NK1.1+ group.
Fig. 6
c Representative immunohistochemical staining of CD8a and NK1.1 in subcutaneously transplanted tumour tissues
×
3.
In Figure S9, the panel of LA-ISA Liver group was misused.
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine
Authors
Zhaojin Yu Wensi Liu Ying He Mingli Sun Jiankun Yu Xue Jiao Qiang Han Haichao Tang Bing Zhang Yunkai Xian Jing Qi Jing Gong Wang Xin Gang Shi Fengping Shan Rui Zhang Jianping Li Minjie Wei
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
